What Is A NHP Study
What Is an NHP Study?
A non-human primate (NHP) study is a preclinical research study that uses non-human primates to evaluate disease mechanisms, drug efficacy, pharmacokinetics (PK), pharmacodynamics (PD), safety, or other biological responses.
NHPs, including cynomolgus and rhesus macaques, share important anatomical, physiological, immunological, and behavioral characteristics with humans. This makes NHP studies particularly valuable when conventional in vitro or rodent models cannot adequately reproduce human disease biology or pharmacological responses.
Why Are NHP Studies Used in Drug Development?
NHP studies are primarily used to address translational questions before clinical development. Depending on the research objective, an NHP study may be designed to evaluate whether a candidate therapy reaches its intended target, produces the expected pharmacodynamic response, improves disease-related endpoints, or exhibits a suitable exposure-response relationship.
NHP models are particularly relevant to therapeutic areas where species-specific biology, complex physiology, or higher-order behavior plays an important role. Applications include CNS and neurological diseases, immunology and inflammation, respiratory diseases, metabolic disorders, infectious diseases, ophthalmology, and other areas of translational medicine.
NHP studies can also incorporate clinically relevant endpoints such as MRI, CT, PET-CT, DSA, behavioral assessments, pathology, and biomarker analysis. These measurements enable longitudinal assessment of disease progression and treatment response while supporting more direct comparison with clinical research endpoints. Prisys' translational research platform integrates NHP disease models with clinical imaging and multidisciplinary pharmacology capabilities.
What Types of NHP Studies Can Be Conducted?
The design of an NHP study depends on the development stage and scientific question. Common study types include:
NHP disease model and efficacy studies - evaluation of candidate drugs in established disease models using clinical, behavioral, imaging, biochemical, pathological, and molecular endpoints.
PK/PD studies - characterization of drug exposure, pharmacokinetic profiles, and pharmacodynamic responses in NHPs.
Safety and tolerability studies - assessment of clinical observations, laboratory parameters, physiological responses, and other safety endpoints.
Target engagement and biomarker studies - investigation of target expression, biological activity, biodistribution, and pharmacodynamic biomarkers.
Imaging and longitudinal studies - use of MRI, CT, PET-CT, DSA, and other imaging technologies to monitor disease progression, drug effects, or biological distribution over time. Prisys' imaging platform is designed to support translational assessment using clinical-equivalent imaging technologies.
Why Choose NHPs for Translational Research?
The primary value of an NHP study is its translational relevance. Compared with many conventional laboratory animal models, NHPs can provide more clinically relevant information for biological pathways, physiological responses, complex behaviors, and certain therapeutic modalities.
However, NHP studies are resource-intensive and should be used when their scientific value justifies the additional complexity. Appropriate species selection, model validation, study design, endpoint selection, veterinary oversight, and ethical review are essential components of a well-designed NHP study.
Prisys provides NHP-based translational research services using established disease models and integrated research capabilities. Its Shanghai Translational Research Center supports animal training, model induction, dosing, sample collection, clinical examination, imaging, pathology, biomarker analysis, and specialized procedures within an integrated research environment.
NHP Studies at Prisys
Prisys Biotech provides non-human primate research services for pharmaceutical and biotechnology companies, covering disease modeling, pharmacology, PK/PD, imaging, biomarker evaluation, and translational research.
The platform supports studies using cynomolgus and rhesus macaques and can integrate multiple endpoints within a single study design. Depending on the project requirements, NHP studies can combine efficacy assessment with PK/PD, clinical imaging, behavioral analysis, pathology, and molecular biomarkers to provide a more comprehensive assessment of therapeutic response.
Prisys' facility is AAALAC-accredited and is designed to support high-quality NHP research with veterinary, surgical, pharmacology, imaging, and analytical capabilities.
FAQ
Q: What does NHP stand for?
A: NHP stands for non-human primate. In preclinical drug development, the term generally refers to primate species used as research models, such as cynomolgus macaques and rhesus macaques.
Q: Why are NHP studies important in drug development?
A: NHPs can provide translational information that may not be adequately captured by in vitro systems or rodent models. Their biological and physiological similarities to humans can be particularly valuable for evaluating therapeutic mechanisms, PK/PD relationships, disease phenotypes, and clinically relevant endpoints.
Q: What types of drugs can be evaluated in NHP studies?
A: NHP studies can support the evaluation of a wide range of therapeutic modalities, including small molecules, antibodies and other biologics, nucleic acid-based therapies, cell and gene therapies, and other novel therapeutic approaches. The appropriate model and study design depend on the mechanism, target, route of administration, and development stage.
Q: What endpoints can be included in an NHP study?
A: Endpoints may include clinical observations, PK/PD parameters, biomarkers, pathology, behavioral measurements, and clinical imaging such as MRI, CT, PET-CT, or DSA. Multiple endpoints can be integrated to provide a more comprehensive assessment of treatment response.
Q: Can NHP studies include both efficacy and PK/PD assessments?
A: Yes. NHP efficacy studies can be designed to incorporate PK sampling and pharmacodynamic assessments, allowing exposure-response relationships to be evaluated alongside disease-related endpoints. This integrated approach can provide useful information for translational dose selection and further development.
Q: How does Prisys support NHP studies?
A: Prisys provides integrated NHP research services covering disease model development, pharmacology, PK/PD, imaging, biomarker analysis, pathology, and specialized procedures. Study designs can be customized according to the scientific objectives and development stage of the candidate therapy.
Hot Tags: what is a nhp study, research, study, monkey, gene therapy, nucleotide PD pharmacology, AMD Nonhuman Primates Disease Model, RNA PD pharmacology, Prisys Nonhuman Primate Disease Models, NHP pharmacodynamics, Delayed type Hypersensitivity DTH Nonhuman Primates Disease Model
Previous
Type 1 Diabetes Mellitus ModelNext
No InformationYou Might Also Like
Send Inquiry